Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. - Wikidata - awgldk - TriplyDB

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.

http://www.wikidata.org/entity/Q34486301

about

The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.Consensus-based recommendations for the management of juvenile dermatomyositis.Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.The Clinical Features of Myositis-Associated Autoantibodies: a Review.The radiology of diffuse interstitial pulmonary disease in children: pearls, pitfalls and new kids on the block in 2015.Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.Serological subsets of juvenile idiopathic inflammatory myopathies--an update.Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease.Enhancing translational research in paediatric rheumatology through standardization.Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis.Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling.Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody.The Vasculopathy of Juvenile Dermatomyositis

P2860

Q37022721-3553361F-6D13-492B-A2FB-46D7DD3BBCE4 Q37388175-8828A41F-3CD1-4B51-B9AA-9815363225EF Q37617000-0A24A95F-FAC6-426D-99B5-2EACD5983FAC Q38281749-CCD580AC-294E-47C2-9571-5ADECC691E3A Q38534871-D893367B-A947-47D8-8527-1159A931BAA6 Q38603422-5C77AAB7-B62A-42FB-AD7E-8F1C97D6572B Q38640876-AE937504-9C89-4AD2-B53C-3A161A867413 Q38646384-D669E78D-8096-4B47-B874-5A29A1A9E995 Q38664251-E21B9FA7-742A-4C87-A6B5-F7A6E5595184 Q38851108-0D981999-9BE4-4601-9B47-B309F3028290 Q38960512-A633D09A-67A9-46BE-87BE-DE6C83183174 Q38999120-49C9528A-46B3-42BB-A953-D14D8DB3CB37 Q39247284-EF118766-46C1-4DC3-9216-E13E70A21374 Q40090384-3CCD5475-D572-43F8-8360-032916F72D6A Q40479791-E0974DFB-F938-48E7-9269-03EFFB94DA55 Q42632915-5B05FEEA-1F70-4CED-A02B-A9258ED160ED Q49998617-3A593E9A-F6B8-4EB5-AF6E-18DCDE80F9E0 Q51090216-E8F6C4E6-FE5F-4865-97AF-BF91681B37F9 Q55311957-2E4E057D-9C73-4822-ACF9-410DC0C9E979 Q57816912-7650D9A8-A7F1-4569-85A7-747BDC0E3406

P2860

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.

http://www.wikidata.org/entity/Q34486301

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@ast

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@en

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@nl

type

label

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@ast

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@en

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@nl

prefLabel

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@ast

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@en

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@nl

P1433

Q34486301-91C68E96-8302-4056-9D4A-A24E02F19D82

P1476

Q34486301-D8D6FFC0-A6A0-42AC-9AB7-BDEBC81C8695

P2093

Q34486301-35287352-8AC3-476F-B32C-C33A6FBBA022

Q34486301-4E5854C5-FF75-4F8C-BBEA-749F8D6BF741

Q34486301-552EA85D-536A-4FFB-9323-76D65D8BE044

Q34486301-8CDD402F-95F5-4C21-8541-F87541B5A5B5

Q34486301-A29D961F-3D8A-49E1-8412-81F23C56E9B0

Q34486301-A379BA37-609E-416E-822C-E6CE00D9EB81

Q34486301-B339BDC8-9678-4081-BB03-A5759217C96C

Q34486301-C061A7B9-B239-463F-9335-3FE7105D36D8

Q34486301-F1CCB0DF-D35B-4E25-9F7C-5839E303B76D

Q34486301-FE5DF77F-1F7D-40E4-8B8B-A322DCA702C1

P2860

Q34486301-031EFD8B-14B7-483E-94EB-FC4B710AF796

Q34486301-0F511B69-1B4A-4F09-8CE5-3D2E6650B3DA

Q34486301-103902AB-0FA1-4204-9151-514DC4696959

Q34486301-161509EA-9712-43DE-9954-E87B7AB86BC3

Q34486301-26AE6347-D8A3-4EA9-97F5-BF6295040A0D

Q34486301-28BE52D8-B0F7-4D64-BBFE-012BF9B3BF95

Q34486301-301B4C52-172C-46D9-B4DD-3416C54E27C9

Q34486301-36ADC0AD-795D-4FA2-8543-5ACBD3541FB6

Q34486301-7CB02134-A68A-4B80-8AF5-9AD58B919B1C

Q34486301-8199DCAA-AB27-4123-8C6C-939DA60CFCD7

P2888

Q34486301-DEE21445-55F8-4F73-9A8E-13F89BF21ABE

P304

Q34486301-CA5E840C-04F1-413B-A0D8-9648EBA66C21

P31

Q34486301-2285E5C4-96FF-402D-A21C-FF3B3546BA3B

P356

Q34486301-BB7BCBC2-1BBC-4950-B2F5-D12AC16F8FAD

P433

Q34486301-F8C7B232-6F3C-451C-BF92-2E9FE6F0E798

P478

Q34486301-5F3B8A6D-CB28-441E-B488-8F0515F74424

P50

Q34486301-2C7444EF-2835-44D0-BE47-C2F7E77D2EDB

Q34486301-6ABE9474-3826-4B94-8A0A-B6CDA1EC920E

P577

Q34486301-8FCA0B88-FDAE-49DE-B9EC-35B85A8BCC60

P5875

Q34486301-9B2B36C4-6A4E-4323-9CA5-C2D157C6F45E

P6179

Q34486301-79F57BBC-BF1A-4955-938C-2A23B111DBB9

P698

Q34486301-42C3051F-4B92-421C-9AA8-28E84FA7B2F5

P921

Q34486301-32166F24-FF11-420B-A983-2C820C35A8A3

Q34486301-F09BCA80-0408-4462-86FD-5A2DD74ADFC2

P932

Q34486301-9FDDCA4E-2BD1-4C1F-B4EC-47DAFBFA1A39

P356

P1433

Arthritis Research and Therapy

P1476

Anti-MDA5 autoantibodies in ju ...... e: a prospective cohort study.

@en

P2093

Catherine M Owens

http://www.w3.org/2001/XMLSchema#string

Clarissa Pilkington

http://www.w3.org/2001/XMLSchema#string

Elena Moraitis

http://www.w3.org/2001/XMLSchema#string

Harsha Gunawardena

http://www.w3.org/2001/XMLSchema#string

Katie Arnold

http://www.w3.org/2001/XMLSchema#string

Neil J McHugh

http://www.w3.org/2001/XMLSchema#string

Shireena Yasin

http://www.w3.org/2001/XMLSchema#string

Thomas S Jacques

http://www.w3.org/2001/XMLSchema#string

UK Juvenile Dermatomyositis Research Group

http://www.w3.org/2001/XMLSchema#string

Zoe E Betteridge

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.

Polymyositis and dermatomyositis (first of two parts).

Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

A systematic review of juvenile-onset clinically amyopathic dermatomyositis.

Diagnosis of interstitial lung diseases.

Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.

International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials.

P2888

P304

R138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR4600

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Lucy R Wedderburn

P577

2014-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263706844

http://www.w3.org/2001/XMLSchema#string

P6179

1019789850

http://www.w3.org/2001/XMLSchema#string

P698

24989778

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis

P932

4227127

http://www.w3.org/2001/XMLSchema#string